Antigens were purified from extracts of Trypanosoma lewisi on immunoadsorbent columns of trypanostatic immunoglobulin G eluted from parasite surface coats at 8 days postinfection. Eight absorbed proteins, with molecular weights between 15,000 and 70,000, were identified. These surface coat antigens (SCAgs) were then used to immunize rats. After immunization, sera were assayed in vitro for levels of circulating trypanostatic and trypanocidal antibodies. Approximately half of the immune sera had higher levels of trypanostatic antibody, compared with control sera; no trypanocidal antibodies (agglutinins) were detected in any of the sera. The rats were then challenged intraperitonally, and the parasitemias and division rates of the parasites were monitored. Parasitemias of all immunized rats were significantly (P < 0.01) lower and of shorter duration than those of the controls. Division rates of trypanosomes were also significantly (P < 0.01) lower in all immunized rats at all times before total cessation of division compared with control rats. A clear dose-response effect was observed, with greater amounts of SCAg eliciting higher levels of protection. Purified SCAgs were also more effective immunogens than were the crude trypanosome extracts from which they had been purified, and in which other proteins in addition to the SCAgs were present. These data provide conclusive evidence that the immunoglobulin G in the surface coats of T. lewisi, adsorbed during the course of infection, is specific antibody, in that it can be used to isolate parasite antigens that elicit a trypanostatic response in rats immunized with them.
In humans and in domestic animals such as cattle, the African trypanosomes can produce a fulminating, rapidly fatal infection or a chronic, insidious disease with debilitating effects (16, 22) . In contrast, these parasites appear to have a well-balanced, benign host-parasite relationship with species of wild antelope, which can serve as reservoir hosts (7, 15, 22) . Parasitemias in these animals are relatively well controlled, reflecting, perhaps, a long evolutionary adaptation, but the basis of this control is unknown.
Trypanosoma lewisi and its natural host, the rat, also show a well-balanced host-parasite relationship. However, it is known that the apparently low pathogenicity of T. lewisi for rats has an immunological basis, and that the parasite is not inherently benign. Thus, if the immune response of the host is impaired (e.g., by corticosteroids, X-irradiation, immunological immaturity, or pregnancy), infections with this parasite can be fulminating and fatal (see references 3, 5, 8) .
In addition to producing conventional trypanocidal antibodies, which are also produced by the hosts of the African trypanosomes, rats infected with T. lewisi produce a trypanostatic antibody that inhibits parasite reproduction without lethal effects. Discovered in 1924 by Taliaferro (20) and subsequently named ablastin by him in 1932 (21) , its identity was controversial for many years because of its apparent non-adsorbability (see references 3, 4, 6 for details of the controversy). Recently, we have shown ablastin to be an adsorbable (6) , specific immunoglobulin G (IgG) antibody, increasing in amount on the surface of trypanosomes during the course of the infection, concomitant with a rise in serum ablastic titer (11) . Furthermore, when such IgG is eluted from the surface coat of the parasite and purified on immunoadsorbent columns of anti-rat IgG, it inhibits parasite reproduction in vitro, whereas purified normal IgG (from serum of uninfected rats) does not (12 and then desorbed with alternating samples of pH 2.5 glycine-hydrochloride (0.025 M in 1 M NaCl) buffer and pH 8.3 borate-buffered saline (0.1 M in 1 M NaCl). Elution of protein was monitored by measuring the absorbance at 280 nm (A280). When elution was complete, the SCIgG column was washed extensively with 0.01 M borate buffer and the adsorbance-desorbance process was repeated. The purified SCAgs from nine such cycles were pooled to give -1.2 mg of SCAgs eluate. The eluate was concentrated by dialysis against dry Sephadex G-200 (Pharmacia Fine Chemicals, Piscataway, N.J.) until it was reduced to -2 ml and dialyzed against 5 liters of phosphate-buffered saline (9) .
When the control immunoadsorbent column made with normal rat IgG was similarly employed, no proteins were detectable after desorption.
Immunization of rats. Purified and crude SCAgs were alum precipitated (13) , and groups of three rats (experiment 1) or six rats (experiment 2) were injected intraperitoneally every 4 to 5 days for a total of five injections per rat. Doses of antigens given in each injection are listed in Table 1 . Control groups received adjuvant alone or no injections.
Evaluation of immunity. Four days after the final injection of antigen, 1 to 2 ml of blood was removed from each rat by cardiac puncture. Sera were prepared as described elsewhere (6) and used for in vitro assays.
These sera were first assayed for trypanocidal antibodies directed against the first or second antigenic variants by agglutination tests with trypanosomes harvested at 4 days postinfection from immunosuppressed rats, or at 15 days postinfection from immunocompetent rats, respectively. Controls included normal rat serum and serum from infected rats that had undergone the first trypanocidal crisis only or had recovered from infection. Trypanosomes were partially purified by differential centrifugation as described elsewhere (12) , washed in Lanham's (14) phosphate buffer, and adjusted to 108 cells per ml. Doubling dilutions of serum were prepared in the same buffer, and 25-p.l volumes of serum and trypanosome suspensions were mixed and incubated at room temperature for 30 min in Linbro 96-well flat-bottom microtiter plates (Flow Laboratories, Inc., McLean, Va.). Agglutination was evaluated microscopically at 100x magnification as described elsewhere (6) .
The sera were also assayed in vitro for trypanostatic activity in Linbro flat-bottom 96-well microtiter plates, using an assay system that was developed for screening hybridomas for trypanostatic activity and is a modification of our standard assay method (12) normal or immune rat serum. The IMDM used throughout contained (per ml) 100 U of penicillin G, 100 p.g of streptomycin, and 0.25 p.g of amphotericin B (GIBCO). Cultures were incubated in a humidified atmosphere of 5% CO2-95% air at 37°C for 16 to 18 h. Giemsa-stained films were then prepared for determinations of division rates.
Immediately after bleeding, rats were challenged intraperitoneally with 105 trypanosomes, and the course of infection was followed by examination of peripheral blood obtained from the tail at 2-to 4-day intervals. Reproductive activity and parasitemias were determined as described in references 6 and 11, respectively. To compare total parasite burdens, an estimate of the area under each parasitemia curve was obtained by summing the median parasitemias observed each day or extrapolated from curves for the duration of the infection.
Protein determinations. Concentrations of protein were determined by the Folin-Ciocalteu reaction as described by Chase and Williams (1). 
RESULTS
Characterization of SCAgs. Results of disc sodium dodecyl sulfate-polyacrylamide gel electrophoresis of surface coat proteins present in extracts of T. lewisi homogenates before and after purification on the SCIgG columns are shown in Fig. 1 . Only approximately 8 of the 22 identifiable trypanosome proteins present in extracts were removed by immunoadsorbance. Molecular weights of the purified proteins ranged from 15,000 to 70,000.
In vitro activity of prechallenge sera from immunized rats.
Immunization with the lowest doses of purified SCAg (5 ,ug in experiment 1, 50 ,ug in experiment 2) did not result in detectable prechallenge levels of circulating trypanostatic antibody (Table 1 ). However, prechallenge sera from rats that had been immunized with higher doses of purified SCAg inhibited trypanosome reproduction in vitro. The means of the latter groups were significantly lower than the controls and were comparable to those obtained with immune sera from rats that experienced a natural infection. It should also be noted that only ca. two-thirds of these sera had detectable inhibitory activity; this is reflected in the relatively high standard deviations of these groups and is an indication of individual variation in response to immunization. Considerably larger amounts of crude antigen than purified antigen were required to produce comparable levels of trypanostatic activity.
No agglutinating (trypanocidal) antibody was detected in any of the sera from the immunized rats. Postive control sera from rats that had experienced a natural infection showed expected levels of agglutinating activity (see reference 3).
Effect of immunization on response to challenge in vivo.
Immunization of rats with crude extracts of T. lewisi and with all doses of purified SCAgs significantly (P < 0.01) reduced the levels of peak parasitemia and the duration of infection compared with controls ( Fig. 2 and 3) . A clear dose-response effect was evident (Fig. 3 ), and immunization with purified SCAg provided significantly higher levels of protection (lower parasite burdens) than the same amount of crude extract (Fig. 4) . It should also be noted that in contrast with the results of in vitro assays for preformed trypanostatic antibody made before challenge (Table 1) , rats immunized with the lowest doses of purified SCAg had significantly lower parasite burdens than did controls. This is most likely the result of a rapid anamnestic response. In addition, ca. 10 to 20% of the rats in the SCAg-immunized groups never developed patent parasitemias after challenge. Inhibition of parasite reproduction occurred earlier and was more pronounced in rats that had been immunized with 50 or 100 ,ug of SCAg, compared with untreated or adjuvantinjected controls (Fig. 5) . Reproductive rates of trypanosomes in SCAg-immunized rats were significantly lower (P < 0.01) than those in controls during the first week postinfection. This very likely occurred because of the presence of preformed trypanostatic antibody at the time of challenge (Table 1 ) and a rapid anamnestic response.
DISCUSSION
The results presented above confirm and extend previous findings that the effector function of SCIgG is trypanostatic (6, 11, 12) . This IgG is clearly adsorbable and specific and can be used on immunoadsorbent columns to isolate antigens that, in microgram quantities, elicit trypanostatic immune responses comparable to those resulting from a natural infection. The results therefore complete a circle of direct evidence that the long-known trypanostatic (ablastic) response to T. lewisi is mediated by a typical IgG immunoglobulin. There is considerable evidence, discussed in detail elsewhere (6, 12) , that trypanostatic antibody exerts its effects by interfering with active membrane transport. It is still not known, however, whether the relevant antigens are actually part of or are adjacent to the transport sites. Furthermore, it remains to be determined whether all of the eight antigens in the purified SCAg preparation used in the current study ( Fig. 1) are required to elicit a trypanostatic response.
Although no agglutinating (trypanocidal) antibody was detectable in any of the prechallenge sera from immunized rats, upon subsequent challenge, there was an earlier trypanocidal response and a rapid termination of infection compared with the controls (Fig. 2 and 3) . There are at least three possible explanations for this early appearance of trypanocidal antibody in vivo. First, although the available evidence, discussed in detail elsewhere (11) , suggests that most, if not all, of the SCIgG is trypanostatic antibody, some of it may be trypanocidal. If so, the purified SCAg preparation obtained with immunoadsorbent columns made with SCIgG may have included some of the first variant antigen in addition to ablastinogen. It should be noted, however, that when rats are passively immunized with trypanostatic antibody and Extract then immediately challenged, they also develop an earlier trypanocidal response than controls (20) ; since there is no prior exposure to parasite antigens under these conditions, the similar accelerated response cannot be due to priming. Second, there is experimental evidence that the specifically incorporated trypanostatic SCIgG may be the target of the second (terminal) trypanocidal antibody, which is an M immunoglobulin (2). Possibly, then, the immunization protocol used in the current study, although clearly eliciting a trypanostatic antibody, may also have resulted in the early production of a rheumatoid-like factor (or an anti-idiotypic antibody), which could have agglutinated the trypanosomes once they became coated with trypanostatic IgG. Thirdly, it may be that expression of the second variant antigen of T. lewisi is modulated by the specific adsorption of trypanostatic IgG, either through a conformational change or through a signal to express the new antigen. The observed earlier production of ablastic IgG would therefore lead to an early expression of the second variant antigen, with subsequent rapid production of its specific trypanocidal antibody. In any event, it is clear that the primary effect of immunization with purified SCAg is a trypanostatic response (Table 1 ; Fig. 5 ), with trypanocidal responses occurring secondarily.
Of practical import is the finding that im ¶qunization with purified, apparently minor components of the cell surface of T. lewisi resulted in significantly higher levels of protection than immunization with similar amounts of crude trypanosome homogenates. The increase achieved in specific activity with purified SCAg suggests that other components in the homogenate, through either antigenic competition or specific immunosuppression, may depress the trypanostatic response. Recently, it has been shown that some antigenic variants of African trypanosomes contain common, accessible antigens that are minor components of the surface coat, which is dominated by the expressed variant antigen (18, 19) . These minor antigens are apparently ignored by the host, but, as suggested by results of the present study, if first purified from variant antigen, such minor components could produce cross-variant protection in animals immunized with them. 
